Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus nebulized acetylcysteine for moderate COPD exacerbation
PACTR202508881358775Phase 3Recruiting
- Sponsor
- Nadda
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of acetylcysteine in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Nadda. Primary endpoint: Improvement in oxygen status. Started Feb 2024; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on PACTR202508881358775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202508881358775.